Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis  by Siddiqi, Nauman et al.
Kidney International, Vol. 65 (2004), pp. 1906–1913
Similar risk profiles for post-transplant renal dysfunction and
long-term graft failure: UNOS/OPTN database analysis
NAUMAN SIDDIQI, MAUREEN A. MCBRIDE, and SUNDARAM HARIHARAN
Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin; and United Network for Organ Sharing,
Richmond, Virginia
Similar risk profiles for post-transplant renal dysfunction and
long-term graft failure: UNOS/OPTN database analysis.
Background. Renal dysfunction measured by serum crea-
tinine (>1.5 mg/dL) at 1 year post-transplant correlates with
long-term kidney graft survival. The purpose of this study was
to compare the risk factors for elevated serum creatinine (SCr)
>1.5 mg/dL at 1 year post-transplantation, and for long-term
graft failure.
Methods. Between 1988 and 1999, 117,501 adult kid-
ney transplants were reported to Organ Procurement and
Transplantation Network/United Network for Organ Sharing
(OPTN/UNOS). Of these, 96,091 were functioning at 1 year and
SCr was available on 85,135 transplants. Donor and recipient
demographics (age, sex, and race), transplant [living vs. cadav-
eric, previous transplantation, panel reactive antibody (PRA),
human leukoocyte antigen (HLA) mismatch, cold ischemic time
(CIT) and post-transplant delayed graft function (DGF), use of
azathioprone vs. mycophenolate mofetil (MMF), cyclosporine
A (CsA) vs. tacrolimus (Tac)], induction antibody, acute rejec-
tion within 1 year variables were used in the logistic regression
model to estimate odds ratio (OR) for elevated 1 year serum
creatinine (SCr). A Cox proportional hazard model was used
to estimate the relative risk (RR) for long-term kidney graft
failure with and without censoring for death with a functioning
graft.
Results. Five-year actuarial graft survival for living donor
transplant with SCr >1.5 and ≤1.5 mg/dL at 1 year post-
transplant was 83% and 88.6% (P < 0.001). The corresponding
values for cadaveric transplant grafts were 66.5% and 77.9%
(P < 0.001). The overall prevalence of renal dysfunction at 1
year post-transplant (SCr >1.5 mg/dL) declined from 54.5%
in 1988 to 42.3% in 1999. There was a strong concordance be-
tween the key variables, such as cadaveric transplant, increas-
ing CIT, HLA mismatch, DGF, and acute rejection, recipient
race (black), younger age, and nondiabetics status; and donor
race (black) and older age for elevated SCr and long-term graft
failure.
Conclusion. Donor (age), race (black), recipient race (black),
immunologic variables (HLA mismatch, DGF, acute rejection)
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were identified as important risk factors for elevated SCr at
1 year post-transplantation and long-term graft failure. Ele-
vated SCr should be used as a short-term marker for predicting
long-term transplant survival.
Renal transplant success is measured by evaluating
short-term end points such as acute rejection rates and
1-year graft survival [1]. Newer immunosuppres-
sive agents such as mycophenolate mofetil (MMF),
tacrolimus (Tac), and sirolimus have been shown to re-
duce short-term acute rejection rates in clinical trials
without impacting short-term survival rates [2–7]. Im-
provements in short- and long-term graft survival rates
after renal transplantation have been noted in a large
database analysis [8]. Short-term survival improvements
coupled with reduced acute rejection rates have less-
ened our ability to measure alternative newer therapies
that can further optimize graft survival. This dilemma
has prompted investigators to evaluate alternative short-
term markers that can predict long-term survival. Post-
transplant renal function is one such surrogate marker
considered for predicting long-term survival [1, 9].
Post-transplant renal function within the first year
has been correlated with long-term survival in single-
center series, as well as in large database analysis [9,
10]. In a recent United Network for Organ Sharing
(UNOS)/Organ Procurement and Transplantation Net-
work (OPTN) analysis, post-transplant serum creatinine
>1.5 mg/dL was shown to be associated with poor long-
term survival [9]. This prompted us to compare factors for
short-term renal dysfunction and long-term graft failure.
The present study compares the risk factors for elevated
serum creatinine (SCr) >1.5 mg /dL at 1 year with risk
factors for long-term graft failure using the UNOS/OPTN
database.
METHODS
All adult renal transplant recipients reported to the
UNOS/OPTN database between 1988 and 1999 that were
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alive with a functioning graft at 1 year post-transplant
were included in the study. Patients that received multior-
gan transplants such as simultaneous kidney and pancreas
grafts were excluded from the analysis. Post-transplant
renal dysfunction at 1 year was defined by elevated SCr
>1.5 mg /dL. Long-term graft failure was defined as
resumption of permanent dialysis therapy, repeat trans-
plantation, or death. Long-term graft failure was also
examined after censoring for death with a functioning
graft.
Potential risk factors for renal dysfunction at 1 year
and long-term graft failure were divided into four groups:
donor, recipient, transplant, and post-transplant factors.
These variables included the following characteristics:
donor (age, sex, and race), recipient [age, sex, race,
cause of end-stage renal disease (ESRD)], pretransplant
maintenance dialysis therapy, previous transplantation],
transplant [living vs. cadaveric, human leukocyte anti-
gen (HLA) mismatch, elevated plasma renin activity
(PRA) >80% vs. ≤80%, cold ischemia time (CIT) in
hours, and transplant year] and post-transplant [delayed
graft function (DFG), clinical acute rejection within 1
year post-transplant, use of antibody induction, and dis-
charge immunosuppression, including use of mycopheno-
late mofetil (MMF) vs. azathioprine (Aza), Cyclosporine
A (CsA) vs. tacrolimus (Tac)].
The Kaplan-Meier method was used to estimate post
1-year actuarial graft survival [11]. A maximum likeli-
hood estimate of the projected half-life (median value)
was calculated assuming exponentially distributed graft
survival times. The analysis did not account for reporting
bias associated with early notification of critical events
(graft failure) and delayed notification for continued sur-
vival. In order to account for differences in characteristics
among patient groups, the odds ratio (OR) for developing
renal dysfunction at 1 year was estimated using a logistic
regression model, and the relative hazard (RH) for long-
term graft failure was estimated using a Cox proportional
hazards model. P values of < 0.05 were considered signif-
icant. All statistical analyses were performed using SAS
version 8.2 (SAS Institute, Cary, NC).
RESULTS
Between 1988 and 1999, a total of 117,501 adult re-
nal transplants were reported to UNOS/OPTN. Among
these, 96,091 renal grafts were functioning at 1-year post-
transplantation, and SCr was available for 85,135 grafts.
Thus, a total of 85,135 transplants were included in this
study. There were 24,701 (29%) living donor transplants
and 60,434 (71%) cadaveric transplants. Of these, 11,283
(13.3%) were repeats, and the remaining 73,852 (86.7%)
were primary grafts. Among these, 41,299 (48.5%) re-
Table 1. Donor and recipient demographics and characteristics for
all renal transplants with 1-year serum creatinine >1.5 and ≤1.5
mg/dL, N (%)
Creatinine Creatinine
≤1.5 mg/dL >1.5 mg/dL P value
N 43,836 (51.5%) 41,299 (48.5%)
Donor type <0.001
LD Tx 13,937 (31.8%) 10,764 (26.1%)
CD Tx 29,899 (68.2%) 30,535 (73.9%)
Donor age >50 years 4,593 (10.6%) 11,398 (27.8%) <0.001
Donor race <0.001
White 34,005 (78.1%) 32,196 (78.0%)
Black 4,050 (9.3%) 4,821 (11.7%)
Other 5,473 (12.6%) 4,042 (9.8%)
Donor sex <0.001
Male 26,688 (60.9%) 21,412 (51.8%)
Female 17,145 (39.1%) 19,885 (48.2%)
Recipient age <0.001
18–34 years 11,283 (25.7%) 12,369 (29.9%)
35–49 years 16,623 (37.9%) 16,720 (40.5%)
≥50 years 15,930 (36.3%) 12,210 (29.6%)
Recipient race <0.001
White 28,961 (66.1%) 25,330 (61.4%)
Black 7,226 (16.5%) 10,894 (26.4%)
Other 7,619 (17.4%) 5,056 (12.2%)
Recipient sex <0.001
Male 21,056 (47.9%) 29,911 (72.4%)
Female 22,780 (51.9%) 11,388 (27.6%)
Pre-tx dialysis <0.001
Yes 37,698 (85.8%) 36,058 (87.3%)
No 3,269 (7.4%) 2,353 (5.2%)
PRA >80% 918 (2.2%) 747 (1.9%) <0.001
Prior transplantation 5,617 (12.8%) 5,666 (13.7%) <0.001
HLA mismatch <0.001
0–2 16,245 (37.8%) 12,976 (32.0%)
3–4 19,266 (44.8%) 19,571 (48.2%)
5–6 7,506 (17.5%) 8,049 (19.8%)
CIT >24 hours 9,815 (25.4%) 11,269 (30.24%) <0.001
DGF Yes 5,264 (12.2%) 8,719 (21.4%) <0.001
AR within 1-year 12,103 (30.0%) 18,044 (47.8%) <0.001
post-tx Yes
Abbreviations are: LD, living donor transplant; CD, cadaver donor transplant;
TX, transplant; DGF, delayed graft function; CIT, cold ischemia time in hours;
AR, acute rejection; HLA, human leukocyte antigen; PRA, panel reactive
antibody.
cipients had elevated SCr >1.5 mg/dL at 1 year post-
transplantation. A total of 23,570 (28%) grafts failed;
8394 (36%) of these failed because of patient death.
Table 1 illustrates differences in the demographic,
transplant, and post-transplant variables for recipients
with 1 year SCr >1.5 and ≤1.5 mg/dL. Those with ele-
vated SCr at 1 year were more likely to be male, black,
and have had a previous transplant. They were less likely
to have the diagnosis of diabetes than recipients with SCr
≤1.5 mg/dL at 1 year. Donor factors were also different.
Those with elevated SCr were more likely to have re-
ceived kidney from a female donor, black donor, or an
older donor. Recipients with SCr >1.5 mg/dL at 1 year
were also more likely to have CIT >24 hours, DGF, acute
rejection within one year, and were less likely to have re-
ceived a well-matched kidney.
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Fig. 1. Post 1-year actuarial kidney graft sur-
vival for living donor grafts without (A) and
with (B) censoring for death with a function-
ing graft according to 1 year serum creatinine
(≤1.5 mg/dL and>1.5 mg/dL).
Figures 1 and 2A and B show the post 1-year actuarial
kidney transplant graft survival for living and cadaveric
recipients with 1-year SCr ≤ and >1.5 mg/dL. Lower
long-term survival was noted in both living (P < 0.001)
and cadaveric (P < 0.001) donor recipients with 1 year
SCr >1.5 mg/dL. The 5-year actuarial graft survival for
living donor recipients with SCr >1.5 and ≤1.5 mg/dL
at 1-year post-transplant were 83% and 88.6%, respec-
tively. The corresponding values for cadaveric grafts were
66.5% and 77.9%, respectively. The differences between
graft survival after living and cadaveric transplantation
with SCr ≤ and >1.5 at 5 years were 5.6 and 11.4 per-
centage points, respectively. The projected median half-
life for grafts from living and cadaveric recipients with
SCr ≤ and >1.5 mg/dL are shown in Figures 3A and
B. The half-lives were approximately halved in recipi-
ents with elevated SCr in both living and cadaveric donor
grafts, compared with those with SCr ≤1.5 mg /dL. The
kidney graft half-lives for living and cadaveric grafts with
SCr ≤1.5 mg/dL was 24.9 and 15.8 years, respectively.
The corresponding values for graft with SCr >1.5 mg/dL
were 13 and 8.3 years, respectively. When censored for
death with a functioning graft the difference in pr ojected
half-lives persisted, however, to a lesser degree between
SCr ≤ and >1.5 mg/dL. Kidney graft half-lives for living
donor kidney grafts with SCr ≤ and >1.5 mg/dL were
44.5 and 17.4 years, respectively. The corresponding val-
ues for cadaveric donor grafts were 31.2 and 11.7 years,
respectively. The difference in graft half-life with elevated
SCr for living and cadaveric donor grafts were 29.8% and
32.7%, respectively.
Table 2 shows the results of the logistic regression anal-
ysis for elevated SCr at 1 year. The parameter estimate,
OR, 95% CI, and P value are shown for recipient, donor,
transplant, and post-transplant variables. Significant vari-
ables associated with increased risk of renal dysfunction
included were: recipient (younger age, black race), donor
(older age, female sex, black race), transplant variables
(DGF), and post-transplant variables (acute rejection
within 1 year).
Table 3 shows the result of the proportionate hazard
analysis for long-term graft failure with and without cen-
soring for death. The RH values were significantly higher
for long-term graft failure for variables such as recipient
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Fig. 2. Post 1-year actuarial kidney graft sur-
vival for cadaver donor grafts without (A) and
with (B) censoring for death with a function-
ing graft according to 1 year serum creatinine
(≤1.5 mg/dL and>1.5 mg/dL).
(older age, black race, diabetes), donor (older age, black
race), transplant (previous transplant, elevated PRA,
cadaveric recipient, DGF) and post-transplant (acute re-
jection within 1 year). The RH values for long-term
graft failure when censored for death were similar ex-
cept for recipient age and diabetes, where the risk of graft
failure was less when death was excluded as a graft failure
(Table 3).
The odds of developing post-transplant renal dysfunc-
tion were higher with the following risk variables: recip-
ient age (34 vs. 44 years), 20%; race (black vs. other),
68%; donor age (44 vs. 34 years), 54%; race (black vs.
other), 36%; DGF, 44%; and acute rejection, 98% (P <
0.0001). The RH values for long-term graft failure were:
recipient age (34 vs. 44 years), 3%; race (black vs. other),
55%; donor age (44 vs. 34 years), 12%; race (black vs.
other), 22%; DGF, 21%; and acute rejection, 34% (P <
0.0001). The RH values for long-term graft failure when
censored for death were: recipient age (34 vs. 44 years),
25%; race (black vs. other), 86%; donor age (44 vs. 34
years), 17%; race (black vs. other), 28%; DGF, 20%; and
acute rejection, 50% (P < 0.0001).
Table 4 shows the OR and RH for selected risk vari-
ables for post-transplant renal dysfunction at 1 year (a),
long-term graft failure including death (b), and long-term
graft failure censoring for death (c). The increased OR
and RH values were similar in magnitude and direction
for many variables, such as recipient (race), donor (age,
race), and transplant (cadaver grafts, CIT, HLA mis-
match, DGF, acute rejection within 1 year), for predicting
post-transplant elevated SCr and long-term graft failure
are shown in Tables 2, 3, and 4. The OR for elevated SCr
and RH values for long-term graft failure were dissimilar
for older recipients, female recipients, and for those who
had diabetes (Tables 2, 3, and 4). However, the RH val-
ues for long-term graft failure decreased when long-term
graft failure was censored for death with a functioning
graft. For example, the RH decreased from 1.48 to 1.08
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Fig. 3. Projected median kidney graft half-
life in years, for living donor (A) and ca-
daver donor (B) kidney grafts according to
1-year serum creatinine (≤1.5 mg/dL and
>1.5 mg/dL) with and without censoring for
death with a functioning graft.
for diabetic recipient, and 1.42 to 0.76 for recipient age
(64 vs. 44 years). Thus, older recipients and those who had
diabetes had higher risk of graft failure because of death
with a functioning graft rather than isolated graft failure.
DISCUSSION
Improvements in short-term graft survival and lower
acute rejection rates have impeded our ability to assess
further advances [1]. Long-term graft survival is an ideal
marker for evaluating future transplant outcome, but im-
practical because of the longer follow-up and large co-
hort of patients that are required to estimate such an
outcome. Hence, it is important to consider short-term
markers, which can predict long-term survival [1], such
as post-transplant renal function [9]. The current study
quantifies the degree of risk profiles for short-term graft
dysfunction and long-term survival.
Post-transplant SCr as a marker is limited, as it varies
by age, sex, race, and body weight. Thus, SCr may
correlate with long-term graft failure without adequate
predictive values. The present study was undertaken to
compare the risk factors for elevated SCr and long-
term graft failure after correcting for various donor, re-
cipient, transplant, and post-transplant variables. The
proportion of recipients with certain demographics,
transplant, and post-transplant variables were different
in those recipients who had SCr >1.5 mg /dL in this
study (Table 1). Appropriately, these recipient, donor
transplant, and post-transplant variables were included
in the logistic regression and proportional hazard mod-
els. Thus, the OR and RH estimations derived in this study
were adjusted for various key risk variables between the
groups.
The odds of developing post-transplant renal dysfunc-
tion at 1 year were higher with certain variables, such
as recipient (younger age, male sex, and black race),
donor (older age, female sex, and black race), transplant
(cadaveric grafts, DGF, HLA mismatch), and post-
transplant variables (acute rejection) (Table 2). These
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Table 2. Logistic regression model for predicting elevated serum
creatinine >1.5 mg/dL at 1-year post-transplantation
Parameter
Variable estimate RH 95% CI P value
Recipient
Age—Linear −0.2056 <0.0001
Age—Quadratic −0.0231 <0.0001
34 vs. 44 1.20 (1.18, 1.23)
54 vs. 44 0.80 (0.78, 0.81)
64 vs. 44 0.60 (0.58, 0.63)
Female vs. male −1.2179 0.30 (0.29, 0.31) <0.0001
Black vs. other 0.5200 1.69 (1.61, 1.76) <0.0001
Diabetic vs. other −0.2867 0.76 (0.72, 0.78) <0.0001
HTN nephrosclerosis −0.0603 0.94 (0.90, 0.99) 0.0150
vs. other
Donor
Age 44 vs. 34 years 0.4366 1.55 (1.53, 1.57) <0.0001
Female vs. male 0.3068 1.36 (1.32, 1.40) <0.0001
Black vs. other 0.3066 1.36 (1.29, 1.44) <0.0001
Transplant
HLA mismatch 0.0390 1.04 (1.03, 1.05) <0.0001
CIT 26 vs. 16 hours 0.0782 1.08 (1.06, 1.10) <0.0001
DGF vs. no DGF 0.3638 1.44 (1.38, 1.50) <0.0001
LD vs. CD −0.0597 0.94 (0.91, 0.98) 0.0033
Post-transplant variables
Antibody induction 0.0629 1.07 (1.03, 1.10) 0.0002
Acute rejection 0.6831 1.98 (1.92, 2.05) <0.0001
within 1-year
MMF vs. other −0.1527 0.86 (0.82, 0.90) <0.0001
TAC vs. CsA −0.2813 0.76 (0.71, 0.80) <0.0001
Abbreviations are: LD, living donor transplant; CD, cadaver donor transplant;
TX, transplant; DGF, delayed graft function; CIT, cold ischemia time in hours; AR,
acute rejection; HLA, human leukocyte antigen; PRA, panel reactive antibody;
MMF, mycophenolate mofetil; TAC, tacrolimus; CsA, cyclosporine.
are well known variables that are known to impact long-
term graft survival [12–16]. Thus, the present study clearly
identifies these risk factors when SCr was used as an end
point instead of long-term survival.
The impact on long-term graft survival was estimated
in the present study by actuarial survival analysis, as well
as projected median graft half-lives. There was a substan-
tial impact on long-term graft survival with elevated SCr
at 1 year for both living and cadaver grafts (Figs. 1 and 2).
Substantial impact on graft survival cannot be attributed
to death, as similar trends were observed when grafts
were censored for death with a functioning graft. It is
possible that this may be caused by a higher proportion
of black recipients, or those who had repeat transplants,
DGF, and increasing degree of HLA mismatches, who
were included in the elevated SCr group. To correct this
bias, these risk factors were included in the Cox model to
control their impact on long-term survival. The present
study detected various well-known risk variables that
impact on long-term graft failure (Tables 3 and 4),
including recipient (age, sex, race), donor (age, sex,
race), transplant (DGF), and post-transplant (acute
rejection).
The present study is the first one to compare the risk
factors between a short-term end point—SCr >1.5 mg
/dL—and long-term graft failure. It is interesting that not
only the risk factors identified, but also the degree of risk,
were similar when estimated by OR and RH methods
(Table 4). The degree of risk profiles for elevated SCr and
long-term graft failure were similar for demographic and
immunologic variables such as black recipients (1.68 vs.
1.55), black donors (1.35 vs. 1.22), HLA mismatch (1.04
vs. 1.05), and acute rejection (1.98 vs. 1.34). Variables
such as recipient age and presence of diabetes revealed
differential magnitude of OR and RH (Table 2); how-
ever, these two risk factors were reduced when long-term
graft failures were censored for death with a functioning
graft (Table 4). These two risk variables are known to
impact long-term survival caused by increased recipient
mortality.
The present study is limited as a result of lack of other
donor and recipient variables such as proteinuria, body
weight, or body mass index (BMI), donor creatinine, and
donor renal histology. Proteinuria remains a hallmark
of renal disease progression and should be included in
predicting renal dysfunction as well as long-term graft
failure. However, this information was not available in
the UNOS/OPTN database. Short- and long-term out-
come of renal transplantation is also dependent on the
quality of the donor kidney. This can be assessed by
the donor’s SCr and or renal histology. Donor histol-
ogy is a better marker over SCr because of limitations
previously mentioned. Transplant outcome is also de-
pendent on donor body weight, which determines daily
creatinine production. Induction antibody therapy as a
variable was not included in this analysis. Preserving re-
nal function through preventing acute rejection may be
achieved with induction of antibody therapy. In this anal-
ysis, acute rejection was used as variable over induction
antibody treatment. Despite these limitations, our anal-
ysis is important as it compares the risk profiles between
short-term end points such as renal function to long-term
graft failure as a gold standard end point of transplant
outcome.
The purpose of this study was to compare the risk fac-
tors for renal dysfunction and long-term graft failure. The
risk characters identified and degree of elevation were
similar. In addition, lower risk profiles identified with re-
cipient age and diabetes were reduced when censored
for death. The present study is limited because it does
not address the positive and negative predictive values
of elevated SCr and long-term graft failure. Despite the
limitations in considering elevated SCr as a short-term
marker for predicting long-term graft outcome, the cur-
rent study clearly illustrates the similarity in risk variables
for elevated SCr and long-term graft failure, and corrob-
orates that elevated SCr at 1 year post-transplantation is
a valid surrogate marker for long-term graft failure. Ele-
vated SCr at 1 year post-transplantation is a biochemical
marker which is widely available and easily reproducible,
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Table 3. Risk factors for long-term graft failure (post 1-year) with and without censoring for death with a functioning kidney using Cox
regression model
Without censoring for death Censoring for death
Variable Parameter estimate RH 95% CI P value Parameter estimate RH 95% CI P value
Recipient
Age—Linear 0.0411 <0.0001 −0.1949 <0.0001
Age—Quadratic 0.0673 <0.0001 0.0275 <.0001
34 vs. 44 years 1.03 (1.01, 1.04) 1.25 (1.23, 1.27)
54 vs. 44 years 1.11 (1.10, 1.13) 0.85 (0.83, 0.86)
64 vs. 44 years 1.42 (1.37, 1.47) 0.76 (0.72, 0.80)
Female vs. male −0.0308 0.97 (0.94, 1.00) 0.0224 0.0476 1.05 (1.02, 1.08) 0.0043
Black vs. other 0.4355 1.55 (1.50, 1.60) <0.0001 0.6205 1.86 (1.79, 1.94) <0.0001
Diabetes vs. other 0.3939 1.48 (1.43, 1.53) <0.0001 0.0750 1.08 (1.03, 1.13) 0.0009
Nephrosclerosis vs. other 0.1943 1.21 (1.17, 1.26) <0.0001 0.1790 1.20 (1.14, 1.25) <0.0001
Donor
Age 44 vs. 34 years 0.1090 1.12 (1.10, 1.13) <0.0001 0.1530 1.17 (1.15, 1.18) <0.0001
Black vs. other 0.1957 1.22 (1.17, 1.27) <0.0001 0.2503 1.28 (1.22, 1.35) <0.0001
Transplant
Previous transplant 0.2894 1.34 (1.29, 1.38) <0.0001 0.3551 1.43 (1.37, 1.49) <0.0001
HLA Mismatch 0.0471 1.05 (1.04, 1.06) <0.0001 0.0628 1.06 (1.05, 1.08) <0.0001
PRA % (>80 vs. <80) 1.1725 1.19 (1.09, 1.29) <0.0001 0.1297 1.14 (1.03, 1.26) 0.0140
CIT (31 vs. 21) 0.0223 1.02 (1.00, 1.04) 0.0130
LD vs. CD 0.2943 0.75 (0.72, 0.77) <0.0001 −0.1902 0.83 (0.79, 0.86) <0.0001
DGF 0.1905 1.21 (1.17, 1.25) <0.0001 0.1844 1.20 (1.16, 1.25) <0.0001
Post-transplant
Acute rejection within 1 year 0.2925 1.34 (1.31, 1.38) <0.0001 0.4068 1.50 (1.45, 1.55) <0.0001
TAC vs. CsA 0.0685 1.07 (1.00, 1.15) 0.0452 0.1438 1.15 (1.07, 1.25) 0.0004
MMF vs. other −0.0778 0.93 (0.88, 0.98) 0.0038 −0.1259 0.88 (0.83, 0.94) <0.0001
Abbreviations are: DGF, delayed graft function; CIT, cold ischemia time in hours; HLA, human leukocyte antigen; LD, living donor; CD, cadaver donor; MMF,
mycophenolate mofetil; CsA, cyclosporine; TAC, tacrolimus.
Table 4. Comparable risk factors for 1-year elevated SCr and
long-term graft failure (post 1-year) with and without censoring for
death with a functioning kidney
Variables OR (95% CI) P value
Risk for elevated SCr at 1 year
Donor age (44 vs. 34 years) 1.55 (1.53, 1.57) <0.0001
Donor—Black vs other 1.36 (1.29, 1.44) <0.0001
Recipient—age (34 vs. 44 years) 1.20 (1.18, 1.23) <0.0001
Recipient—Black vs. other 1.69 (1.61, 1.76) <0.0001
Recipient—Female vs. male 0.30 (0.29, 0.31) <0.0001
Recipient—Diabetes vs. no diabetes 0.76 (0.72, 0.78) <0.0001
DGF vs. no DGF 1.44 (1.38, 1.50) <0.0001
HLA mismatch 1.04 (1.03, 1.05) <0.0001
Acute rejection within 1 year 1.98 (1.92, 2.05) <0.0001
Risk for all long-term (post-1 year) graft failure
Donor age (44 vs. 34 years) 1.12 (1.10, 1.13) <0.0001
Donor—Black vs. other 1.22 (1.17, 1.27) <0.0001
Recipient—age (34 vs. 44 years) 1.03 (1.01, 1.04) <0.0001
Recipient—Black vs. other 1.55 (1.50, 1.60) <0.0001
Recipient—Female vs. male 0.97 (0.94, 1.00) 0.0224
Recipient—Diabetes vs. no diabetes 1.48 (1.43, 1.53) <0.0001
DGF vs. no DGF 1.21 (1.17, 1.25) <0.0001
HLA mismatch 1.05 (1.04, 1.06) <0.0001
Acute rejection within 1 year 1.34 (1.31, 1.38) 0.0038
Risk for long-term (post-1 year) graft failure after censoring for death
Donor age (44 vs. 34 years) 1.17 (1.15, 1.18) <0.0001
Donor—Black vs. other 1.28 (1.22, 1.35) <0.0001
Recipient—age (34 vs. 44 years) 1.25 (1.23, 1.27) 0.0043
Recipient—Black vs. other 1.86 (1.79, 1.94) <0.0001
Recipient—Female vs. male 1.05 (1.02, 1.08) NS
Recipient—Diabetes vs. no diabetes 1.08 (1.03, 1.13) 0.0009
DGF vs. no DGF 1.20 (1.16, 1.25) <0.0001
HLA mismatch 1.06 (1.05, 1.08) <0.0001
Acute rejection within 1 year 1.50 (1.45, 1.55) <0.0001
Abbreviations are: DGF, delayed graft function; HLA, human leukocyte anti-
gen.
making it a convenient marker for evaluating transplant
outcome.
CONCLUSION
Short-term post-transplant renal dysfunction is asso-
ciated with long-term graft failure. Characteristics asso-
ciated with elevated SCr at 1 year are similar to those
associated with long-term graft failure. Elevated SCr at
1 year is a reasonable surrogate marker for evaluating
transplant outcome.
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